03 Profile
Vital Signsby Bridgehead
Hansard to 11 November 2026 · 31,429 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Academic · Rare diseases
Vincent Dion: no photograph is held, so the academic plate is shown instead.
Academic
Vincent Dion
Professor at the UK Dementia Research Institute at Cardiff University; leader of the research team
3
0
Oct 2026Nov 2026to date
3
press citations on 1 topic since 22 Oct 2026 · last quoted 28 Oct 2026
02 Quoted on · 1 of 29 topics
Vincent Dion: key facts
- Kind of voice
- Academic
- Role
- Professor at the UK Dementia Research Institute at Cardiff University; leader of the research team
- Quoted on
- Rare diseases
- Tracked press citations
- 3
- Most recently quoted
- 28 Oct 2026
- First quoted
- 22 Oct 2026
04 The signal · where Vincent Dion sits on rare diseases
Ranked 12= of 100 voices quoted in the press on rare diseases, level with 12 others on 3 citations.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- 1Giles LomaxSector leaderChief Executive Officer, Spinal Muscular Atrophy UK (SMA UK)9
- 2Dr Harrison CarterAcademicDirector of Screening at NHS England8
- 3=
Prof Dame Sue HillRegulatorChief Scientific Officer for England and Senior Responsible Officer for Genomics, NHS England7 - 8=
Jessica LeeSector leaderDirector of Research, My Name'5 Doddie Foundation4 - 12=Louise ParkesSector leaderChief executive, Great Ormond Street Hospital Charity3
- 12=Vincent DionAcademicProfessor at the UK Dementia Research Institute at Cardiff University; leader of the research team3
- 12=Sikha de SouzaClinicianPublic Health Consultant, Public Health Wales3
- 12=Lucy CliffeClinicianConsultant Paediatrician, Paediatric Immunology Service, Nottingham Children's Hospital3
Showing the leaders and the ranks around 12=, of 100 voices · See every voice on the topic →
05 On the record · press
What Vincent Dion has said
By outlet · linked articles
- medicalxpress.com1
- nrtimes.co.uk1
- regmednet.com1
Where Vincent Dion has been quoted
- 01Gene editing could transform Huntington’s treatment – studynrtimes.co.uk · 28 Oct 2026
- 02Cas9 nickase: a promising gene-editing approach for Huntington’s diseaseregmednet.com · 27 Oct 2026
- 03New gene-editing approach shows promise in treating Huntington's disease in micemedicalxpress.com · 22 Oct 2026
Verbatim
“The length of these repeated sequences accounts for most of the variation in how severe the disease is, so targeting and reducing these sequences is a potentially viable therapeutic avenue.”
“The length of these repeated sequences accounts for most of the variation in how severe the disease is, so targeting and reducing these sequences is a potentially viable therapeutic avenue.”
“The length of these repeated sequences accounts for most of the variation in how severe the disease is, so targeting and reducing these sequences is a potentially viable therapeutic avenue.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
- Coventry tot's heartbreaking health battle after 'extremely rare' diagnosiscoventrytelegraph.net
- Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdlereuters.com
- 'Immoral lottery' - Mum's plea after losing daughter to rare diseasethewestmorlandgazette.co.uk
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 10 Nov 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.